The global Sustained and Controlled Release Formulations market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Sustained and Controlled Release Formulations is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Sustained and Controlled Release Formulations is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Sustained and Controlled Release Formulations is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Sustained and Controlled Release Formulations players cover Humanwell Healthcare Co.,Ltd., Nanjing Yiheng Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co.,ltd., Qilu Pharmaceutical Co Ltd, Shanghai Pharmaceuticals Holding Co.,Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淪ustained and Controlled Release Formulations Industry Forecast鈥� looks at past sales and reviews total world Sustained and Controlled Release Formulations sales in 2024, providing a comprehensive analysis by region and market sector of projected Sustained and Controlled Release Formulations sales for 2025 through 2031. With Sustained and Controlled Release Formulations sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sustained and Controlled Release Formulations industry.
This Insight Report provides a comprehensive analysis of the global Sustained and Controlled Release Formulations landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sustained and Controlled Release Formulations portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Sustained and Controlled Release Formulations market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sustained and Controlled Release Formulations and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sustained and Controlled Release Formulations.
This report presents a comprehensive overview, market shares, and growth opportunities of Sustained and Controlled Release Formulations market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Generic Drug
Original Drug
Segmentation by Application:
Cardiovascular System Drugs
Nervous System Drugs
Digestive System and Metabolism
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Humanwell Healthcare Co.,Ltd.
Nanjing Yiheng Pharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co.,ltd.
Qilu Pharmaceutical Co Ltd
Shanghai Pharmaceuticals Holding Co.,Ltd.
Yangtze River Pharmaceutical (Group) Co., Ltd.
PKU HealthCare Corp.,Ltd.
Overseas Pharmaceuticals, Ltd.
Novast Laboratories (China), LTD.
Catalent
AstraZeneca Plc
Oakwood Labs
Ascendia Pharma
Colorcon
Pfizer Inc.
Mylan
Sandoz
Key Questions Addressed in this Report
What is the 10-year outlook for the global Sustained and Controlled Release Formulations market?
What factors are driving Sustained and Controlled Release Formulations market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Sustained and Controlled Release Formulations market opportunities vary by end market size?
How does Sustained and Controlled Release Formulations break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Sustained and Controlled Release Formulations Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Sustained and Controlled Release Formulations by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Sustained and Controlled Release Formulations by Country/Region, 2020, 2024 & 2031
2.2 Sustained and Controlled Release Formulations Segment by Type
2.2.1 Generic Drug
2.2.2 Original Drug
2.3 Sustained and Controlled Release Formulations Sales by Type
2.3.1 Global Sustained and Controlled Release Formulations Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Sustained and Controlled Release Formulations Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Sustained and Controlled Release Formulations Sale Price by Type (2020-2025)
2.4 Sustained and Controlled Release Formulations Segment by Application
2.4.1 Cardiovascular System Drugs
2.4.2 Nervous System Drugs
2.4.3 Digestive System and Metabolism
2.4.4 Other
2.5 Sustained and Controlled Release Formulations Sales by Application
2.5.1 Global Sustained and Controlled Release Formulations Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Sustained and Controlled Release Formulations Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Sustained and Controlled Release Formulations Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Sustained and Controlled Release Formulations Breakdown Data by Company
3.1.1 Global Sustained and Controlled Release Formulations Annual Sales by Company (2020-2025)
3.1.2 Global Sustained and Controlled Release Formulations Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Sustained and Controlled Release Formulations Annual Revenue by Company (2020-2025)
3.2.1 Global Sustained and Controlled Release Formulations Revenue by Company (2020-2025)
3.2.2 Global Sustained and Controlled Release Formulations Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Sustained and Controlled Release Formulations Sale Price by Company
3.4 Key Manufacturers Sustained and Controlled Release Formulations Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Sustained and Controlled Release Formulations Product Location Distribution
3.4.2 Players Sustained and Controlled Release Formulations Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Sustained and Controlled Release Formulations by Geographic Region
4.1 World Historic Sustained and Controlled Release Formulations 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Sustained and Controlled Release Formulations Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Sustained and Controlled Release Formulations Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Sustained and Controlled Release Formulations 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Sustained and Controlled Release Formulations Annual Sales by Country/Region (2020-2025)
4.2.2 Global Sustained and Controlled Release Formulations Annual Revenue by Country/Region (2020-2025)
4.3 Americas Sustained and Controlled Release Formulations Sales Growth
4.4 APAC Sustained and Controlled Release Formulations Sales Growth
4.5 Europe Sustained and Controlled Release Formulations Sales Growth
4.6 Middle East & Africa Sustained and Controlled Release Formulations Sales Growth
5 Americas
5.1 Americas Sustained and Controlled Release Formulations Sales by Country
5.1.1 Americas Sustained and Controlled Release Formulations Sales by Country (2020-2025)
5.1.2 Americas Sustained and Controlled Release Formulations Revenue by Country (2020-2025)
5.2 Americas Sustained and Controlled Release Formulations Sales by Type (2020-2025)
5.3 Americas Sustained and Controlled Release Formulations Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Sustained and Controlled Release Formulations Sales by Region
6.1.1 APAC Sustained and Controlled Release Formulations Sales by Region (2020-2025)
6.1.2 APAC Sustained and Controlled Release Formulations Revenue by Region (2020-2025)
6.2 APAC Sustained and Controlled Release Formulations Sales by Type (2020-2025)
6.3 APAC Sustained and Controlled Release Formulations Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Sustained and Controlled Release Formulations by Country
7.1.1 Europe Sustained and Controlled Release Formulations Sales by Country (2020-2025)
7.1.2 Europe Sustained and Controlled Release Formulations Revenue by Country (2020-2025)
7.2 Europe Sustained and Controlled Release Formulations Sales by Type (2020-2025)
7.3 Europe Sustained and Controlled Release Formulations Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Sustained and Controlled Release Formulations by Country
8.1.1 Middle East & Africa Sustained and Controlled Release Formulations Sales by Country (2020-2025)
8.1.2 Middle East & Africa Sustained and Controlled Release Formulations Revenue by Country (2020-2025)
8.2 Middle East & Africa Sustained and Controlled Release Formulations Sales by Type (2020-2025)
8.3 Middle East & Africa Sustained and Controlled Release Formulations Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Sustained and Controlled Release Formulations
10.3 Manufacturing Process Analysis of Sustained and Controlled Release Formulations
10.4 Industry Chain Structure of Sustained and Controlled Release Formulations
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Sustained and Controlled Release Formulations Distributors
11.3 Sustained and Controlled Release Formulations Customer
12 World Forecast Review for Sustained and Controlled Release Formulations by Geographic Region
12.1 Global Sustained and Controlled Release Formulations 麻豆原创 Size Forecast by Region
12.1.1 Global Sustained and Controlled Release Formulations Forecast by Region (2026-2031)
12.1.2 Global Sustained and Controlled Release Formulations Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Sustained and Controlled Release Formulations Forecast by Type (2026-2031)
12.7 Global Sustained and Controlled Release Formulations Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Humanwell Healthcare Co.,Ltd.
13.1.1 Humanwell Healthcare Co.,Ltd. Company Information
13.1.2 Humanwell Healthcare Co.,Ltd. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.1.3 Humanwell Healthcare Co.,Ltd. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Humanwell Healthcare Co.,Ltd. Main Business Overview
13.1.5 Humanwell Healthcare Co.,Ltd. Latest Developments
13.2 Nanjing Yiheng Pharmaceutical Co., Ltd.
13.2.1 Nanjing Yiheng Pharmaceutical Co., Ltd. Company Information
13.2.2 Nanjing Yiheng Pharmaceutical Co., Ltd. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.2.3 Nanjing Yiheng Pharmaceutical Co., Ltd. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Nanjing Yiheng Pharmaceutical Co., Ltd. Main Business Overview
13.2.5 Nanjing Yiheng Pharmaceutical Co., Ltd. Latest Developments
13.3 Jiangsu Hengrui Pharmaceuticals Co.,ltd.
13.3.1 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Company Information
13.3.2 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.3.3 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Main Business Overview
13.3.5 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Latest Developments
13.4 Qilu Pharmaceutical Co Ltd
13.4.1 Qilu Pharmaceutical Co Ltd Company Information
13.4.2 Qilu Pharmaceutical Co Ltd Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.4.3 Qilu Pharmaceutical Co Ltd Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Qilu Pharmaceutical Co Ltd Main Business Overview
13.4.5 Qilu Pharmaceutical Co Ltd Latest Developments
13.5 Shanghai Pharmaceuticals Holding Co.,Ltd.
13.5.1 Shanghai Pharmaceuticals Holding Co.,Ltd. Company Information
13.5.2 Shanghai Pharmaceuticals Holding Co.,Ltd. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.5.3 Shanghai Pharmaceuticals Holding Co.,Ltd. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Shanghai Pharmaceuticals Holding Co.,Ltd. Main Business Overview
13.5.5 Shanghai Pharmaceuticals Holding Co.,Ltd. Latest Developments
13.6 Yangtze River Pharmaceutical (Group) Co., Ltd.
13.6.1 Yangtze River Pharmaceutical (Group) Co., Ltd. Company Information
13.6.2 Yangtze River Pharmaceutical (Group) Co., Ltd. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.6.3 Yangtze River Pharmaceutical (Group) Co., Ltd. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Yangtze River Pharmaceutical (Group) Co., Ltd. Main Business Overview
13.6.5 Yangtze River Pharmaceutical (Group) Co., Ltd. Latest Developments
13.7 PKU HealthCare Corp.,Ltd.
13.7.1 PKU HealthCare Corp.,Ltd. Company Information
13.7.2 PKU HealthCare Corp.,Ltd. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.7.3 PKU HealthCare Corp.,Ltd. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 PKU HealthCare Corp.,Ltd. Main Business Overview
13.7.5 PKU HealthCare Corp.,Ltd. Latest Developments
13.8 Overseas Pharmaceuticals, Ltd.
13.8.1 Overseas Pharmaceuticals, Ltd. Company Information
13.8.2 Overseas Pharmaceuticals, Ltd. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.8.3 Overseas Pharmaceuticals, Ltd. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Overseas Pharmaceuticals, Ltd. Main Business Overview
13.8.5 Overseas Pharmaceuticals, Ltd. Latest Developments
13.9 Novast Laboratories (China), LTD.
13.9.1 Novast Laboratories (China), LTD. Company Information
13.9.2 Novast Laboratories (China), LTD. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.9.3 Novast Laboratories (China), LTD. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Novast Laboratories (China), LTD. Main Business Overview
13.9.5 Novast Laboratories (China), LTD. Latest Developments
13.10 Catalent
13.10.1 Catalent Company Information
13.10.2 Catalent Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.10.3 Catalent Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Catalent Main Business Overview
13.10.5 Catalent Latest Developments
13.11 AstraZeneca Plc
13.11.1 AstraZeneca Plc Company Information
13.11.2 AstraZeneca Plc Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.11.3 AstraZeneca Plc Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 AstraZeneca Plc Main Business Overview
13.11.5 AstraZeneca Plc Latest Developments
13.12 Oakwood Labs
13.12.1 Oakwood Labs Company Information
13.12.2 Oakwood Labs Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.12.3 Oakwood Labs Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Oakwood Labs Main Business Overview
13.12.5 Oakwood Labs Latest Developments
13.13 Ascendia Pharma
13.13.1 Ascendia Pharma Company Information
13.13.2 Ascendia Pharma Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.13.3 Ascendia Pharma Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Ascendia Pharma Main Business Overview
13.13.5 Ascendia Pharma Latest Developments
13.14 Colorcon
13.14.1 Colorcon Company Information
13.14.2 Colorcon Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.14.3 Colorcon Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Colorcon Main Business Overview
13.14.5 Colorcon Latest Developments
13.15 Pfizer Inc.
13.15.1 Pfizer Inc. Company Information
13.15.2 Pfizer Inc. Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.15.3 Pfizer Inc. Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Pfizer Inc. Main Business Overview
13.15.5 Pfizer Inc. Latest Developments
13.16 Mylan
13.16.1 Mylan Company Information
13.16.2 Mylan Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.16.3 Mylan Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Mylan Main Business Overview
13.16.5 Mylan Latest Developments
13.17 Sandoz
13.17.1 Sandoz Company Information
13.17.2 Sandoz Sustained and Controlled Release Formulations Product Portfolios and Specifications
13.17.3 Sandoz Sustained and Controlled Release Formulations Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Sandoz Main Business Overview
13.17.5 Sandoz Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
